1. Home
  2. UBX vs KAPA Comparison

UBX vs KAPA Comparison

Compare UBX & KAPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UBX
  • KAPA
  • Stock Information
  • Founded
  • UBX 2009
  • KAPA 2013
  • Country
  • UBX United States
  • KAPA United States
  • Employees
  • UBX N/A
  • KAPA N/A
  • Industry
  • UBX Biotechnology: Pharmaceutical Preparations
  • KAPA
  • Sector
  • UBX Health Care
  • KAPA
  • Exchange
  • UBX Nasdaq
  • KAPA NYSE
  • Market Cap
  • UBX 24.6M
  • KAPA 21.3M
  • IPO Year
  • UBX 2018
  • KAPA 2024
  • Fundamental
  • Price
  • UBX $1.00
  • KAPA $1.71
  • Analyst Decision
  • UBX Strong Buy
  • KAPA Strong Buy
  • Analyst Count
  • UBX 1
  • KAPA 1
  • Target Price
  • UBX $8.00
  • KAPA $9.00
  • AVG Volume (30 Days)
  • UBX 82.0K
  • KAPA 102.5K
  • Earning Date
  • UBX 11-04-2024
  • KAPA 11-14-2024
  • Dividend Yield
  • UBX N/A
  • KAPA N/A
  • EPS Growth
  • UBX N/A
  • KAPA N/A
  • EPS
  • UBX N/A
  • KAPA N/A
  • Revenue
  • UBX N/A
  • KAPA N/A
  • Revenue This Year
  • UBX N/A
  • KAPA N/A
  • Revenue Next Year
  • UBX $33.62
  • KAPA N/A
  • P/E Ratio
  • UBX N/A
  • KAPA N/A
  • Revenue Growth
  • UBX N/A
  • KAPA N/A
  • 52 Week Low
  • UBX $1.00
  • KAPA $1.22
  • 52 Week High
  • UBX $2.02
  • KAPA $4.00
  • Technical
  • Relative Strength Index (RSI)
  • UBX 28.85
  • KAPA N/A
  • Support Level
  • UBX $1.10
  • KAPA N/A
  • Resistance Level
  • UBX $1.23
  • KAPA N/A
  • Average True Range (ATR)
  • UBX 0.06
  • KAPA 0.00
  • MACD
  • UBX -0.01
  • KAPA 0.00
  • Stochastic Oscillator
  • UBX 0.00
  • KAPA 0.00

About UBX Unity Biotechnology Inc.

Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.

About KAPA KAIROS PHARMA LTD

Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.

Share on Social Networks: